MPN Watch

Dossier web review May 30, 2026

Latest Advancements in Myelofibrosis Treatment: Key Updates from EHA and ASH 2025

Key claim: Updated clinical and real-world evidence for JAK inhibitors in myelofibrosis and emerging pipeline therapies were highlighted at EHA and ASH 2025 conferences.

Abstract

Expert commentary from leading hematologists discussing updated clinical and real-world evidence for JAK inhibitors in myelofibrosis and new pipeline approaches from ASH and EHA 2025 conferences.

Why this matters

Pending synthesis.

Source

Link

Briefing card

Latest Advancements in Myelofibrosis Treatment: Key Updates from EHA and ASH 2025
Stage: review · web · May 30, 2026

Updated clinical and real-world evidence for JAK inhibitors in myelofibrosis and emerging pipeline therapies were highlighted at EHA and ASH 2025 conferences.

Cross-references (0)

None recorded — doctrine links and citations appear here as scans and citation sweeps find them.

External: url:https://www.emjreviews.com/hematology/article/latest-advancements-in-myelofibrosis-treatment-key-updates-from-eha-and-ash-2025/

Ask about this finding

Replies are grounded in the abstract and metadata above. The model will quote directly when possible and say so if a question isn't covered.

Subscribe: calendar of upcoming dates · deadlines feed · all new records · Help

build build 612 · 69ce4cf-dirty · 2026-11-11